pharmaphorum

JUNE 24, 2021

Lucentis has been approved by the FDA since 2006 for wet AMD and is a big earner for both Roche and Novartis, who share rights to the product with Roche selling the drug in the US and Novartis selling it in Europe and other markets. Wet AMD is a leading cause of blindness for people aged 60 and over and affects approximately 1.1

Diabetes

European Pharmaceutical Review

SEPTEMBER 21, 2023

In this Q&A, Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring summarises key considerations for gene therapy drug development and the ideal approach for alleviating economic strain when advancing these modern treatments. 4,5 What is the key consideration drug developers should apply to gene therapies?

Drug Development

Pharmaceutical Technology

JANUARY 26, 2023

Patients with conditions with limited treatment options could one day be cured by these breakthrough therapeutics, with treatments for everything from cancers, Parkinson’s and Alzheimer’s to strokes, spinal cord injuries and diabetes. Scottish Enterprise was instrumental in setting up RoslinCT and its predecessor, Rosin Cells.

Communication

PharmaShots

FEBRUARY 27, 2023

As a renowned chemist, Dr. Senanayake discussed the need to adopt green chemistry in the process of drug development for cost reduction, timely innovation, and generating less waste than the standard process. Dr. Joe Armstrong Dr. Joe presented on the Blockbuster Drug Januvia: An Innovators Perspective.

Biosimilars

PharmaTech

JUNE 23, 2025

Drug Z, 50 mg. cardiac, immunogenicity, hepatic, diabetes) affecting compounding and drug dosage must be known. Drug Enforcement Administration. USDOJ.gov , May 2006 (accessed April 29, 2025). 100 capsules. One capsule four times daily The medication order is received and evaluated.

Compounding